Known targets — ChEMBL curated mechanism
POLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PRIM1PRIM2RRM1RRM2RRM2B
The experimentally established mechanism targets of Fludarabine Phosphate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA5A | P35218 | 1/20 | 1.00 |
| ▸ | NT5E | P21589 | 6/20 | 0.82 |
| ▸ | P2RY1 | P47900 | 8/20 | 0.73 |
| ▸ | P2RY11 | Q96G91 | 5/20 | 0.73 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.73 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.73 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.73 |
| ▸ | LDHA | P00338 | 1/20 | 0.73 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.73 |
| ▸ | FBP1 | P09467 | 1/20 | 0.73 |
| ▸ | SRC | P12931 | 1/20 | 0.73 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.73 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.73 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.73 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.73 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.73 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.73 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.73 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fludarabine Phosphate SCHEMBL14565620 | 1.00 | CA5A (1.00) | CA5ANT5EP2RY1P2RY11DNPH1 | |
| Fludarabine Phosphate SCHEMBL3511 | 1.00 | CA5A (1.00) | CA5ANT5EP2RY1P2RY11DNPH1 | |
| Fludarabine Phosphate SCHEMBL1650192 | 1.00 | CA5A (1.00) | CA5ANT5EP2RY1P2RY11DNPH1 | |
| Fludarabine Phosphate SCHEMBL13046080 | 1.00 | CA5A (1.00) | CA5ANT5EP2RY1P2RY11DNPH1 | |
| Fludarabine Phosphate SCHEMBL17541855 | 1.00 | CA5A (1.00) | CA5ANT5EP2RY1P2RY11DNPH1 | |
| Fludarabine Phosphate SCHEMBL23884975 | 1.00 | CA5A (1.00) | CA5ANT5EP2RY1P2RY11DNPH1 | |
| Fludarabine Phosphate SCHEMBL899922 | 1.00 | CA5A (1.00) | CA5ANT5EP2RY1P2RY11DNPH1 | |
| Fludarabine Phosphate SCHEMBL8401646 | 1.00 | CA5A (1.00) | CA5ANT5EP2RY1P2RY11DNPH1 | |
| Fludarabine Phosphate SCHEMBL21173132 | 1.00 | CA5A (1.00) | CA5ANT5EP2RY1P2RY11DNPH1 | |
| Fludarabine Phosphate SCHEMBL30350656 | 1.00 | CA5A (1.00) | CA5ANT5EP2RY1P2RY11DNPH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 139 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2011528275-A | — | — | 2011-11-17 | — | — | JP | claimed |
| EP-2313122-A1 | DRUG DELIVERY MEDICAL DEVICE | Micell Technologies, Inc. (US) | 2011-04-27 | — | — | EP | claimed |
| WO-2010009335-A1 | DRUG DELIVERY MEDICAL DEVICE | MICELL TECHNOLOGIES, INC. (US) | 2010-01-21 | — | — | WO | claimed |
| US-7148207-B2 | For therapy of cancer; quick release tablet of fludarabine phosphate in a defined composition of residual contaminants | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-12-12 | — | — | US | claimed |
| EP-1455760-B1 | ULTRAPURE ORAL FLUDARA FORMULATION WITH A FAST RELEASING ACTIVE SUBSTANCE | SCHERING AG (DE) | 2005-09-07 | — | — | EP | claimed |
| US-20030176391-A1 | Oral fludara of high-purity formulation with quick release of active ingredient | SCHERING AG (DE) | 2003-09-18 | — | — | US | claimed |
| JP-56029599-A | — | — | None | — | — | JP | disclosed |
| US-20240156764-A1 | INHIBITION OF URACIL DNA GLYCOSYLASE IN THE OPEN CONFORMATION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-05-16 | — | — | US | disclosed |
| CN-116814621-A | RNA inhibitor for inhibiting APOC3 gene expression and application thereof | 厦门甘宝利生物医药有限公司 | 2023-09-29 | — | — | CN | disclosed |
| CN-115572726-A | siRNA for inhibiting PCSK9 gene expression and application thereof | 上海君实生物医药科技股份有限公司 | 2023-01-06 | — | — | CN | disclosed |
| CN-115572725-A | siRNA for inhibiting ANGPTL3 gene expression and application thereof | 上海君实生物医药科技股份有限公司 | 2023-01-06 | — | — | CN | disclosed |
| CN-115397436-A | RNAi agents for inhibiting PNPLA3 expression, pharmaceutical compositions and methods of use thereof | 箭头药业股份有限公司 | 2022-11-25 | — | — | CN | disclosed |
| CN-114072142-A | Combination therapy for the treatment of hepatitis B virus infection | 杨森制药公司 | 2022-02-18 | — | — | CN | disclosed |
| US-6063787-A | SKIN DISORDERS TREATMENT WITH AMINOPYRIMIDONES SUBSTITUTED WITH HETEROCYCLIC DIETHERS | THE UNIVERSITY OF GEORGIA RESEARCH FOUNDATION CENTER (US) | 2000-05-16 | — | — | US | disclosed |
| US-6025343-A | Lipid esters of nucleoside monophosphates and their use as immunosuppressive drugs | ROCHE DIAGNOSTICS GMBH (DE) | 2000-02-15 | — | — | US | disclosed |
| WO-1999043691-A1 | 2'-FLUORONUCLEOSIDES | EMORY UNIVERSITY (US) | 1999-09-02 | — | — | WO | disclosed |
| US-5817667-A | 1-(2-HYDROXYMETHYL-1,3-DIOXOLAN-4-YL)CYTOSINE | UNIVERSITY OF GEORGIA RESEARCH FOUDATION (US) | 1998-10-06 | — | — | US | disclosed |
| EP-0781136-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1997-07-02 | — | — | EP | disclosed |
| WO-1996007413-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1996-03-14 | — | — | WO | disclosed |
| JP-S5629599-A | NOVEL 2-FLUORO-O2'-MONOACYL-ADENOSINE-3',5'-CYCLIC PHOSPHATE, ITS PREPARATION AND CARCINOSTATIC AGNET CONTAINING THE SAME | KIKKOMAN CORP | 1981-03-24 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176391-A1 | Oral fludara of high-purity formulation with quick release of active ingredient | CYP2C19, FCGR2A, CYP2C9 | CA5A 2336/4885NT5E 604/4885P2RY1 16/4885 |
| US-20240156764-A1 | INHIBITION OF URACIL DNA GLYCOSYLASE IN THE OPEN CONFORMATION | UNG, OGG1, MPG | CA5A 2498/4885NT5E 193/4885P2RY1 3778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.